tiprankstipranks

Aclaris Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with a $20 price target after the company entered into an exclusive license agreement with privately-held Biosion. The “transformative” licensing transaction revitalizes the company’s pipeline with renewed focus on biologic candidates, the analyst tells investors in a research note. The firm ascribes a 30% probability of approval to BSI-045B in chronic asthma and a 20% probability of approval to this candidate in atopic dermatitis. It also believes Aclaris’ legacy pipeline programs may generate additional value.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue